High scoop! If you compare the number of times there were adverse events on the drug to the placebo you’ll see there isn’t an issue. I’d love to see the reference from BI. It’s unusual for a pharma company to say their drug has a safer profile when they haven’t done their phase 3 trial yet. However, I agree that it’ll be wonderful to have choices.